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ABSTRACT
Chemotherapy dose calculation for oncologycal patient is using the human 
body surface area (BSA). BSA is a variable with a difficult constitutional body 
and physiological assessment. BSA does not reflect the exercise on body com-
position in relation to the various body modifications: obesity, amputation of 
body parts, pregnancy. Body surface area despite the documented limitations 
remains the most commonly used parameter chemotherapy (cytotoxic therapy) 
of cancer patients.
The new guidelines are intended obese patients is to achieve the same maxi-
mum dose rate calculated BSA taking into account the full weight rather than 
using the statement or reduce weight by restricting intake. Experience shows 
that there are significant restrictions on the dosage given on BSA in obese 
patients, amputation of a body part or to become pregnant.
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characteristics
Chemotherapy dose calculation for oncologycal patient is using the human 
body surface area (BSA). Body surface area is expressed in square meters (m2). 
BSA is a variable with a difficult constitutional body and physiological assess-
ment. But the BSA does not reflect the exercise on body composition in rela-
tion to the various body modifications: obesity, amputation of body parts, preg-
nancy. It is believed that the average BSA value for adults is 1.73 m2 (Table 1). 
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Body surface area despite the documented limitations remains the most com-
monly used parameter chemotherapy (cytotoxic therapy) of cancer patients.[1]
Table 1. Body surface area value depending of the age and gender
Body surface area (m²)
Newborns
Children under 2 years of age
  Children under 9 years of age
Children under 10 years of age
12–13 years old children
Male
Female
There are different approaches to chemotherapy dose is calculated in a situa-
tion where any missing body parts such as amputation. One of the possibilities 
is the standard BSA determination taking into account height and weight before 
amputation (Figure 1).
19.0%
15.0%
6.0%
1.8%
6.5%
3.0%
1.0%
Figure 1. The percentage weight loss of total body weight the missing part or all of the 
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For example, if the patient has a below knee amputation then subtracted from 
the body weight of 6% for the amputation above the knee, then to subtract 15% 
of the body weight. If the whole foot is amputated then minus 19%[2].
The dose can be adjusted based on the reduction of BSA by the formula 
when deprived of the limb volume or dose adjustments are made on the basis 
of the reduced weight [3,4]. Accurate to calculate the dose of chemotherapy 
in such cases, a lack of supporting evidence there is no data from clinical trials 
or guidelines. It does not account for other influencing factors such as age, co-
morbidities, pharmacogenetics processes and other. There are changes in phar-
macokinetics due to altered body composition, decrease in the size of vascular 
and cardiac ejection fraction, but the drug metabolism and excretion remains 
unchanged. The renal function is used to assess serum creatinine in the case of 
amputation is not always an accurate indicator of [5].
Obesity is one of the risk factors which may cause cancer especially in coun-
tries with a high standard of living. Obesity affects processes which may cause 
carcinogenic such as tumor necrosis factor alpha(TNF-α) increase, estrogen 
production increasing in the fat. [6]. There is an association between obe-
sity and endometrial, colon, pancreas and breast cancer increases the risk of. 
There is an association between obesity and endometrial, colon, pancreas and 
breast cancer increases the risk of [7]. Obesity is considered a chronic disease 
in which the body fat mass than lean body mass (fat free mass) which is meas-
ured by the body mass index (BMI) of 30 kg/m2 or more [8,9]. Over the past 
25 years obesity as a cause of death is about 14% of men and 20% of women 
with a diagnosis of cancer. Population of overweight and obesity in the period 
in 1980 to 2005 year has increased from 15 to 35% [10]. Obese women till 80% 
increased risk of developing breast cancer stage III and IV low degree of differ-
entiation (p = 0.014) than women with normal weight [8]. Recent years have 
been intensely studied the relationship between obesity and breast cancer as 
the poor etiological and prognostic factors in patients with an increased body 
mass. By the 1990th the data published in the literature show that an increase in 
body weight, increasing the risk of breast cancer recurrence from 1.78 to 1.91, 
but the relative risk of death – from 1.36 to 1.56 [11]. Taking into account the 
ratio between total mortality and body mass index the World Health Organiza-
tion (WHO) has recommended that the desirable BMI is in the range between 
20 and 25 kg/m2. If a BMI greater than 25 kg/m2 the patient has overweight 
(Table 2). BMI <20 kg/m2 is defined as underweight.
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Table 2. The degree of obesity
The degree of obesity BMI (kg/m2)
I 25–29
II 30–39
III  40
Relationship between obesity and breast cancer prognosis is widely studied. 
Studies since 1988. the prognosis is worse for patients with obesity, especially 
in post-menopausal women at diagnosis [12]. In one of the last statements 
has shown that obesity is associated with poor prognosis in pre-menopausal 
and menopausal women. Obesity as a prognostic indicator associated with a 
less favorable prognosis, especially for a large breast tumors and an increased 
amount of lymph nodes involved. Is the dominant hypothesis of adipose tissue 
volume effect of hormone levels. Increased body fat volume is associated with 
elevated serum estrogen levels. This increase is achieved by converting andro-
gens by the aromatase enzyme in adipose tissue and reduced sex hormone 
binding globulin which lowers estrogen activity. The growing influence of 
estrogen in the blood of breast cancer development and growth rate. It should 
be noted that pre-menopausal and menopausal women have different hormone 
levels and it is important that breast cancer is dependent on estrogen receptors 
[12]. Pharmacokinetic studies have shown that chemotherapy dose calcula-
tion should take into account the actual (real) rather than the ideal body weight 
[13]. Chemotherapy-induced neutropenia may be a pharmacokinetic marker 
(surrogate). Several studies have shown that the incidence of neutropenia after 
the course of chemotherapy improving the “disease-free” or overall survival out-
comes in the later years [14, 15]. Retrospective study (Lopes-Serrão, etc.) have 
been reported [16] a common practice – the maximum doses of chemotherapy 
in obese patients undergoing cancer chemotherapy. The duration of treatment 
and hematologic toxicity were compared with patients with obesity receiving 
cancer chemotherapy based on a cap body surface area of   2.2 m2, and normal 
weight patients. Hematological toxicity for cancer patients with the risk of obe-
sity receiving a full or nearly full doses of chemotherapy no greater than normal 
weight patients receiving full dose according to body weight. There are stud-
ies that show that up to 40% of patients with obesity receive reduced doses of 
chemotherapy which are not based on actual body weight[17].38  |  A. Geri￿a-B￿rzi￿a, U. Vikmanis, G. Purkalne, S. Umbraško
In view of the foregoing the ASCO (American Society of Clinical Oncol-
ogy) the organization has proposed to develop evidence-based clinical practice 
guidelines on the application of chemotherapy for cancer patients with obesity. 
A group of experts from various clinical disciplines aimed at collecting the most 
common questions raised by oncologists in their daily practice. To address 
these issues and to create a practical evidence-based recommendations, the 
expert group stressed the need for retrospective and prospective studies. One 
of the new trends of modern chemotherapy is a target therapy (biological and 
molecular therapy) and combination with conventional myelosuppressive cyto-
toxic agents for cancer patients. Targeted therapy needed for evidence-based 
clinical practice guidelines to determine the dose of chemotherapy for cancer 
patients with obesity. This is to reduce persistent uncertainty a more coherent 
dosing and improved clinical outcomes.
Approximately from 0.02 to 0.1% of pregnant women are diagnosed cancer. 
More common are the neck, breast cancer (10% for women younger than 40 
years), Hodgkin’s lymphoma and melanoma. The chemotherapy during preg-
nancy do not intend and does not. The theory recommending chemotherapy 
take into account several parameters: lipophilicity, drug molecular weight, pro-
tein binding capacity of P-glycoprotein and CYP (cytochrome enzyme) in the 
blood. During pregnancy prolonged drug elimination half-life time, deficiency 
of the metabolite, can have all kinds of toxicity. For the purposes of dose is not 
entirely clear data on the treatment schedule (every one to three weeks), which 
is the standard dose (insufficient or excessive), take into account the continu-
ous changes in body weight [38lu]. Clinical and pharmacokinetic studies in 
such cases is difficult because the pregnancy is hormonal, bioavailability and 
distribution, metabolism and excretion changes, increasing water and fat in the 
body, in addition to take into account the amniotic fluid. Blood flow through 
the liver and kidneys increases by 50–80% [18]. There is still a lack of infor-
mation on the optimal chemotherapy dosing strategies, with benefit / risk. It 
is impossible to predict the risk for the mother and the fetus / baby. Each new 
clinical case must be examined individually.
American Oncology Association has developed a general agreement that 
obese patients should be given the optimal chemotherapy dose that provides 
clinical benefit in reduced dose intensity may compromise disease-free sur-
vival (DFS) and overall survival (OS). Historically dose determination in obese 
patients has been problematic and so far there has been no standard approach. 
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The new guidelines are intended obese patients is to achieve the same maxi-
mum dose rate calculated BSA taking into account the full weight rather than 
using the statement or reduce weight by restricting intake. However, experi-
ence shows that there are significant restrictions on the dosage given on BSA in 
obese patients, amputation of a body part or to become pregnant.
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